Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction: Molecular Diagnosis

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 3, 2008, Pages 955-961

  Cruz Gonzalez, Ignacio ^a   Pabón, Pedro ^a   Rodríguez Barbero, Alicia ^b   Martín Moreiras, Javier ^a   Pericacho, Miguel ^b   Sánchez, Pedro L ^c   Ramirez, Victor ^a   Sánchez Ledesma, María ^a   Martín Herrero, Francisco ^a   Jiménez Candil, Javier ^a   Maree, Andrew O ^d   Sánchez Rodríguez, Angel ^a   Martín Luengo, Cándido ^a   López Novoa, José M ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Endoglin; Endothelial dysfunction; Myocardial infarction; Prognostic markers

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PROSPECTIVE STUDY; ROC CURVE; STATISTICAL MODEL; TIME;

AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; ROC CURVE; TIME FACTORS;

EID: 41049096406     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00156.x     Document Type: Article

References (28)

1. Carmeliet P. Mechanism of angiogenesis and arteri-ogenesis. Nat Med. 2000 6 : 389 95.
2. Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM, Simoons ML CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation. 2003 107 : 524 30.
3. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothe-lial cells. J Biol Chem. 1990 265 : 8361 4.
4. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signalling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem. 1999 274 : 584 94.
5. MacAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnnon WC, Murrell J, MCCormick MK, Perick-Vance MA, Heutink P, Oostra BA, Haitjema T, Westerman CJJ, Porteus ME, Guttmacher AE, Letarte M, Marchuk DA. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994 8 : 345 51.
6. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem. 2002 277 : 43799 808.
7. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003 17 : 984 92.
8. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med. 2004 2 : 18.
9. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP. Defective angiogenesis in mice lacking endoglin. Science. 1999 284 : 1534 7.
10. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest. 1999 104 : 1343 51.
11. Venkatesha S, Toporsian M, Lam C, Hanai JI, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006 12 : 642 9.
12. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006 355 : 992 1005.
13. Velasco-Loyden G, Arribas J, Lopez-Casillas F. The shedding of betaglycan is regulated by pervana-date and mediated by membrane type matrix metal-loprotease-1. J Biol Chem. 2004 279 : 7721 33.
14. Libby P. Current concepts of the pathogenesis of acute coronary syndromes. Circulation. 2002 104 : 365 72.
15. Schmidt R, Bultmann A, Ungerer M, Joghetaei N, Bulbul O, Thieme S, Chavakis T, Toole BP, Gawaz M, Schomig A, May AE. Extracellular matrix metal-loproteinase inducer regulates matrix metallopro-teinase activity in cardiovascular cells:implications in acute myocardial infarction. Circulation. 2006 113 : 834 41.
16. Rajavashisth TB, Xu X-P, Jovinge S, Meisel S, Xu X-O, Chai N-N, Fishbein MC, Kaul S, Cercek B, Sharifi B, Shah PK. Membrane type 1 matrix metal-loproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation. 1999 99 : 3103 9.
17. Wilson EM, Moainie SL, Baskin JM, Lowry AS, Deschamps AM, Mukherjee R, Guy TS, St John-Sutton MG, Gorman JH 3rd., Edmunds LH Jr., Gorman RC, Spinale FG. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation. 2003 107 : 2857 63.
18. Helisch A, Schaper W. Arteriogenesis:the development and growth of collateral arteries. Microcirculation. 2003 10 : 83 97.
19. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003 9 : 653 60.
20. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000 342 : 626 33.
21. Kranz A, Rau C, Kochs M, Waltenberger J. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J Mol Cell Cardiol. 2000 32 : 65 72.
22. Kawamoto A, Kawata H, Akai Y, Katsuyama Y, Takase E, Sasaki Y, Tsujimura S, Sakaguchi Y, Iwano M, Fujimoto S, Hashimoto T, Dohi K. Serum levels of VEGF and basic FGF in the subacute phase of myocardial infarction. Int J Cardiol. 1998 67 : 47 54.
23. Lee K, Lip G, Blann A. Plasma Angiopoietin-1, Angiopoietin-2, Angiopoietin Receptor Tie-2 and vascular Endothelial Growth Factor Levels in Acute Coronary Syndromes. Circulation. 2004 110 : 2355 60.
24. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005 23 : 233 46.
25. Jerkic M, Rivas-Elena JV, Prieto M, Carron R, Sanz-Rodriguez F, Perez-Barriocanal F, Rodriguez-Barbero A, Bernabeu C, Lopez-Novoa JM. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J. 2004 18 : 609 11.
26. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005 96 : 684 92.
27. Jerkic M, Rodríguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV, Obreo J, Chan A, Pérez-Barriocanal F, Arévalo M, Bernabéu C, Letarte M, López-Novoa JM. Reduced angiogenic responses in adult endoglin heterozy-gous mice. Cardiovasc Res. 2006 69 : 845 54.
28. Duwel A, Eleno N, Jerkic M, Arevalo M, Bolanos JP, Bernabeu C, Lopez-Novoa JM. Reduced tumor growth and angiogenesis in endoglin-haploinsuffi- cient mice. Tumour Biol. 2007 28 : 1 8.